PDS Biotechnology price target lowered to $3 from $5 at B. Riley

PDSB +9.08%

B. Riley lowered the firm’s price target on PDS Biotechnology (PDSB) to $3 from $5 and keeps a Buy rating on the shares. The shares remain attractively valued with near-zero EV that fails to reflect impact of this recent strategic pivot on enrollment size, efficacy endpoint durations and an enriched p16+ve population with limited competing trials, the analyst tells investors in a research note.

TipRanks Black Friday Sale

• Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.

• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on PDSB:

Disclaimer & DisclosureReport an Issue

• VTI ETF Daily Report—11/20/2025

• PDS Biotechnology: Promising Trial Results and Financial Update

• PDS Biotechnology’s Earnings Call: Clinical Wins Amid Financial Hurdles

• PDS Biotechnology price target raised to $15 from $13 at H.C. Wainwright

• PDS Biotechnology reports Q3 EPS (19c), consensus (20c)